Inhibikase Therapeutics (IKT) Interest Coverage Ratio (2020 - 2022)

Inhibikase Therapeutics (IKT) has reported Interest Coverage Ratio for 6 consecutive years, with 0.44 the latest figure, recorded in Q4 2025.

• In Q4 2025, Interest Coverage Ratio changed N/A year-over-year to 0.44; the TTM figure through Dec 2025 stood at 1.64 (changed N/A YoY), while the FY2025 annual figure was 1.64, down 78.59% from the prior year.
• Interest Coverage Ratio advanced to 0.44 in Q4 2025 per IKT's latest filing, from 282.66 in the prior quarter.
• Across five years, Interest Coverage Ratio topped out at 273.1 in Q4 2021 and bottomed at 28477.96 in Q3 2021.
• Historically, Interest Coverage Ratio has averaged 2826.65 across 5 years, with a median of 152.87 in 2023.
• On a YoY basis, Interest Coverage Ratio climbed as much as 262.36% in 2021 and fell as far as 29463.13% in 2021.
• Inhibikase Therapeutics' Interest Coverage Ratio stood at 273.1 in 2021, then slumped by 123.51% to 64.2 in 2022, then plunged by 130.15% to 147.76 in 2023, then surged by 74.27% to 38.02 in 2024, then jumped by 98.86% to 0.44 in 2025.
• Business Quant data shows IKT's Interest Coverage Ratio at 0.44 in Q4 2025, 282.66 in Q2 2025, and 7798.08 in Q1 2025.